{'52WeekChange': -0.7179104,
 'SandP52WeekChange': 0.0644362,
 'address1': 'One Kendall Square',
 'address2': 'Building 1400E Suite 14-105',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1,
 'askSize': 800,
 'averageDailyVolume10Day': 157650,
 'averageVolume': 94406,
 'averageVolume10days': 157650,
 'beta': None,
 'beta3Year': None,
 'bid': 0.9,
 'bidSize': 1400,
 'bookValue': 1.558,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 0.9888,
 'dayLow': 0.9287,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': 0.399,
 'enterpriseToRevenue': None,
 'enterpriseValue': -6655739,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 1.3037143,
 'fiftyTwoWeekHigh': 3.493,
 'fiftyTwoWeekLow': 0.514,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 3083179,
 'forwardEps': -0.6,
 'forwardPE': -1.5833333,
 'fromCurrency': None,
 'fullTimeEmployees': 16,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.18972999,
 'heldPercentInstitutions': 0.27813998,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/anchiano.com',
 'longBusinessSummary': 'Anchiano Therapeutics Ltd, a clinical-stage '
                        'biotechnology company, develops gene therapies to '
                        'treat early-stage bladder cancer. It is primarily '
                        'developing Inodiftagene that is in various clinical '
                        'trials for the treatment of non-muscle-invasive '
                        'bladder cancer. The company was formerly known as '
                        'BioCancell Ltd. and changed its name Anchiano '
                        'Therapeutics Ltd in July 2018. The company was '
                        'founded in 2004 and is headquartered in Cambridge, '
                        'Massachusetts.',
 'longName': 'Anchiano Therapeutics Ltd',
 'market': 'us_market',
 'marketCap': 7048876,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_29091338',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -20746000,
 'nextFiscalYearEnd': 1640908800,
 'open': 0.9888,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '857-259-4622',
 'previousClose': 0.975,
 'priceHint': 4,
 'priceToBook': 0.6097561,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 0.9888,
 'regularMarketDayLow': 0.9287,
 'regularMarketOpen': 0.9888,
 'regularMarketPreviousClose': 0.975,
 'regularMarketPrice': 0.9888,
 'regularMarketVolume': 35971,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 7419870,
 'sharesPercentSharesOut': 0.0023999999,
 'sharesShort': 14275,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 5007,
 'shortName': 'Anchiano Therapeutics Ltd.',
 'shortPercentOfFloat': None,
 'shortRatio': 0.19,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'ANCN',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.793,
 'twoHundredDayAverage': 1.1008633,
 'volume': 35971,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.anchiano.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}